Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00197) | |||||
---|---|---|---|---|---|
Name |
Diflunisal
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
diflunisal; 22494-42-4; Dolobid; Dolobis; Fluniget; Flovacil; Fluodonil; Adomal; Flustar; 5-(2,4-Difluorophenyl)salicylic acid; MK-647; 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid; Diflusinal; MK 647; 5-[2,4-Difluorophenyl]salicylic acid; 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid; 2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid; [1,1'-Biphenyl]-3-carboxylic acid, 2',4'-difluoro-4-hydroxy-; C13H8F2O3; UNII-7C546U4DEN; 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID; 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid; 2',4'-Difluoro-4-hydroxy[1,1'-biphenyl]-3-carboxylic acid; MFCD00057834; 2',4'-Difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid; CHEMBL898; MLS000028678; 7C546U4DEN; Algobid; Citidol; Difludol; Noaldol; Reuflos; 3-BIPHENYLCARBOXYLIC ACID, 2',4'-DIFLUORO-4-HYDROXY-; CHEBI:39669; Unisal; (1,1'-Biphenyl)-3-carboxylic acid, 2',4'-difluoro-4-hydroxy-; 2',4'-difluoro-4-hydroxy-biphenyl-3-carboxylic acid; NCGC00016765-01; Diflunisalum; Dolisal; Dolobil; SMR000058723; 2',4'-difluoro-4-hydroxy-[1,1'-biphenyl]-3-carboxylic acid; CAS-22494-42-4; DSSTox_CID_2932; DSSTox_RID_76792; DSSTox_GSID_22932; Diflunisalum [INN-Latin]; Dolobid (TN); SR-01000003165; EINECS 245-034-9; BRN 2654431; Diflunisal (JAN/USP/INN); Diflunisal-d3; Prestwick_168; Diflunisal [USAN:USP:INN:BAN:JAN]; PubChem14748; Spectrum_000962; Opera_ID_803; Prestwick0_000039; Prestwick1_000039; Prestwick2_000039; Prestwick3_000039; Spectrum2_001012; Spectrum3_000392; Spectrum4_000513; Spectrum5_000901; SCHEMBL4337; BSPBio_000137; BSPBio_002203; KBioGR_001085; KBioSS_001442; MLS001146895; BIDD:GT0063; DivK1c_000938; SPECTRUM1500245; SPBio_001163; SPBio_002058; Diflunisal, analytical standard; BPBio1_000151; GTPL7162; DTXSID5022932; HMS502O20; KBio1_000938; KBio2_001442; KBio2_004010; KBio2_006578; KBio3_001423; ZINC20243; NINDS_000938; HMS1568G19; HMS1920G10; HMS2090C16; HMS2091M20; HMS2095G19; HMS3259G17; HMS3712G19; HMS3885H10; Pharmakon1600-01500245; BCP09905; Tox21_110598; BDBM50240510; CCG-40230; NSC756728; SBB058143; AKOS005762917; Tox21_110598_1; DB00861; KS-1346; MCULE-8281018918; NC00506; NSC-756728; IDI1_000938; NCGC00016765-02; NCGC00016765-03; NCGC00016765-04; NCGC00016765-05; NCGC00016765-06; NCGC00016765-08; NCGC00016765-09; NCGC00022783-03; NCGC00022783-04; AK161747; HY-18342; SBI-0051347.P003; AB0013252; DB-045934; AB00051969; CS-0007468; FT-0630487; ST51014978; C01691; D00130; J10103; AB00051969-12; AB00051969_13; A816230; 2',4'-difluoro-4-hydroxybipheny-3-carboxylic acid; J-014739; Q2602750; SR-01000003165-2; SR-01000003165-3; 5-[2,4-bis(fluoranyl)phenyl]-2-oxidanyl-benzoic acid; BRD-K22031190-001-05-3; BRD-K22031190-001-13-7; Diflunisal, European Pharmacopoeia (EP) Reference Standard; 2',4'-Difluoro-4-hydroxy-(1',1-diphenyl)-3-carboxylic acid; Diflunisal, United States Pharmacopeia (USP) Reference Standard; 1286107-99-0
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Osteoporosis | ICD-11: FB83 | [1] | ||
PubChem CID | |||||
Formula |
C13H8F2O3
|
||||
Canonical SMILES |
C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O
|
||||
InChI |
1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)
|
||||
InChIKey |
HUPFGZXOMWLGNK-UHFFFAOYSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=3059"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 250.2 | Topological Polar Surface Area | 57.5 | |
XlogP | 4.4 | Complexity | 311 | ||
Heavy Atom Count | 18 | Rotatable Bond Count | 2 | ||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 5 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Diflunisal 500 mg tablet | Click to Show/Hide the Full List of Formulation(s): 7 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Fd&c blue no. 2; Fd&c yellow no. 6; Titanium dioxide; Croscarmellose sodium; Polyethylene glycol 400; Silicon dioxide; Cellulose, microcrystalline; Hypromelloses; Starch, pregelatinized corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Cadila Healthcare; Zydus Pharmaceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sunset yellow FCF | DIG Info | Solute carrier SLCO2B1 (Ki = 68.4 uM) | [2] | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [3] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Polyethylene glycol 400 | DIG Info | Albendazole monooxygenase (IC50 = 10.77 mg.mL-1) | [6] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Fd&c blue no. 2; Indigotindisulfonate sodium; Propylene glycol; Titanium dioxide; Croscarmellose sodium; Cellulose, microcrystalline; Hypromellose 2910 (15 mpa.s); Hypromellose 2910 (6 mpa.s); Starch, corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | PD-Rx Pharmaceuticals; Teva Pharmaceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [3] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [4] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [6] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Drug Formulation 3 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Fd&c blue no. 2; Indigotindisulfonate sodium; Propylene glycol; Titanium dioxide; Croscarmellose sodium; Hypromellose 2910 (15 mpa.s); Hypromellose 2910 (6 mpa.s); Microcrystalline cellulose; Starch, corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | A-S Medication Solutions; Carilion Materials Management | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [3] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [4] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [6] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Drug Formulation 4 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Fd&c blue no. 2; Indigotindisulfonate sodium; Propylene glycol; Titanium dioxide; Croscarmellose sodium; Cellulose, microcrystalline; Hypromellose 2910 (15 mpa.s); Hypromellose 2910 (6 mpa.s); Starch, corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | H. J. Harkins Company | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [3] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [4] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [6] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Drug Formulation 5 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Fd&c blue no. 2; Propylene glycol; Titanium dioxide; Croscarmellose sodium; Cellulose, microcrystalline; Hypromelloses; Starch, corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Lake Eire Medical & Surgical Supply DBA Quality Care Products; Rising Pharmaceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [3] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [4] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [6] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Drug Formulation 6 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Fd&c blue no. 2; Propylene glycol; Titanium dioxide; Croscarmellose sodium; Aluminum oxide; Cellulose, microcrystalline; Hypromelloses; Starch, corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | A-S Medication Solutions | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [3] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [4] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [6] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Drug Formulation 7 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium stearyl fumarate; Fd&c blue no. 2; Propylene glycol; Titanium dioxide; Croscarmellose sodium; Cellulose, microcrystalline; Hypromelloses; Starch, corn
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Physicians Total Care | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
FD&C blue no. 2 | DIG Info | Adenosine receptor A3 (IC50 = 1 uM) | [3] | |||
Sodium stearyl fumarate | DIG Info | Leukemia K562 cells (IC50 = 20.2 ug.mL-1) | [4] | |||
Propylene glycol | DIG Info | Albendazole monooxygenase (Inhibition ratio < 20 %) | [6] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.